Discovery Life Sciences

Today, we are celebrating a series of groundbreaking advancements that mark the start of a new era for Discovery. The official opening of our brand-new state-of-the-art facilities in Huntsville, AL, and Alameda, CA, the launch of revolutionary Olink Explore HT services, and our revitalized website together will amplify our ability to empower scientists on a global scale.    "This trifecta of advancements signifies a profound moment in our journey," said Discovery CEO Glenn Bilawsky. "From Alameda to Huntsville, from the physical to the digital, we're reshaping the future of life sciences. We're more equipped than ever to catalyze innovations that have the potential to transform lives."  - Glenn Bilawsky, CEO of Discovery Life Sciences Visit our new website to learn more: https://lnkd.in/gHr-CZZ2

It’s estimated that every 3 minutes, someone in the US is diagnosed with a form of blood cancer. Leukemia and lymphoma alone represent 80% of all new cases: https://lnkd.in/emuArfjg Discovery is committed to supporting oncology research and providing starting cellular materials for cell and gene therapies, which are setting new therapeutic benchmarks for leukemias and lymphomas. Join us in advancing the fight against blood cancers and making a difference in patients' lives. #BloodCancerAwarenessMonth #Leukemia #Lymphoma #Oncology 

Sacituzumab Govitecan (SG), an antibody-drug conjugate (ADC) approved for breast cancer, shows promise in treating brain metastases from breast cancer (BCBM) and recurrent glioblastoma (rGBM), according to results from a prospective trial at the University of Texas Health Science Center at San Antonio. Read more: https://lnkd.in/g5S_Zv9p    ADC therapy is a revolutionary approach designed to target specific tumor cells with high precision while minimizing toxicity to healthy cells. Discovery has helped many ADC therapy developers adopt robust, sensitive, and clinical trial ready assays:  https://lnkd.in/gA7nHFxD    Discovery’s cell biology experts are also experienced in assessing off-target toxicity and linker stability for potential ADC therapies: https://lnkd.in/gUqjFDpw    Speak with our ADC experts today.      #CancerResearch #ADC #BreastCancer #Glioblastoma  

Adaptimmune makes history with the first-ever FDA approval of an engineered TCR-T cell therapy for solid tumors. TECELRA® (afamitresgene autoleucel) is the first new treatment option for patients with metastatic synovial sarcoma (SS) in over a decade. This breakthrough offers new hope for metastatic SS patients and showcases the transformative potential of cell and gene therapies in the fight against challenging cancers.  Read more: https://lnkd.in/gp68yd6U #SolidTumors #CellTherapy 

Are you attending the World CB&CDx Summit in Boston next week? We invite all our biopharma and diagnostics partners and customers to an exclusive event on Day 2, Sep 5th, at 12:50p. Dr.Staci J Kearney, PhD, RAC,  Founder & Chief Executive Officer at Elevation Strategic Development LLC, will be presenting on “The Nuances of Biomarker Implementation in a Clinical Trial: A Regulatory Perspective.” Looking forward to meeting you there! #BiomarkerDiscovery #companiondiagnostics #WorldCDx #biomarkers 

Discover the critical role of HLA typing in the development of both autologous and allogeneic CAR-T cell therapies. Learn how different HLA typing technologies are used to optimize CAR constructs, enhance donor-recipient matching, and support the development of universal CAR-T cells.    Read the new blog post: https://lnkd.in/gG2XzxDU 

Come join Discovery Life Sciences at the 14th World CB&CDx Summit in Boston from September 3-6. Visit us at Booth #26 or schedule a meeting with our experts to discuss how our specialty lab services can advance your biomarker programs. We look forward to seeing you! https://lnkd.in/gaGRqtHT  #BiomarkerDiscovery #companiondiagnostics #WorldCDx #biomarkers 

Discovery has recently released many FFPE tissues, double-spun plasma (DSP), and dissociated tumor cells (DTCs) with 2-year patient follow-up data, collected from nearly 400 oncology patients across various indications. This dataset includes information on treatment regimens, response rates, and more, providing valuable insights into disease progression and treatment responses. Reserve today: https://lnkd.in/dgZkE5i4 The patient follow-up data can be utilized to analyze cancer progression and patient response to treatment over time. This information can improve study cohort selection, deepen the understanding of resistance mechanisms, and aid in the development of more effective therapies. Our biospecimen experts are actively working on expanding our longitudinal data collection to other sample types such as PBMCs, buffy coats, and flash-frozen tissues. Connect with us to learn more: https://lnkd.in/dgZkE5i4 #Oncology #CancerResearch #Biospecimens

Immunizations play a vital role in global public health by preventing the spread of diseases. Despite the benefits, increasing vaccine uptake can be challenging. This is especially true for illnesses like the flu where people may be reluctant to keep up with recommended annual vaccinations.  New research from Oregon Health & Science University offers hope for a universal flu vaccine. By targeting a stable internal viral protein, this novel approach offers a “one and done” solution that could offer lifetime immunity. If successful, this platform has the potential to change the vaccination landscape. https://lnkd.in/gxtT6NHp At Discovery, we recognize the importance of immunization and are committed to supporting researchers worldwide with high-quality products and services to advance vaccine development.  #NationalImmunizationAwarenessMonth #Vaccines 

Read about the promising results of a recent CAR-T therapy study. https://lnkd.in/erWcyBB5